Original articleAsthma, lower airway diseasesExploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire
Introduction
Asthma guidelines have focused on maintaining and improving asthma control as the goal of therapy and have categorized control into 3 levels: controlled or well controlled, partially controlled or not well controlled, and uncontrolled or very poorly controlled.[1], [2] Several instruments have been developed to measure asthma control. One example, the Asthma Control Questionnaire (ACQ) has been used extensively as a standardized measure3 and has been designated as a core measure for research supported by the National Institutes of Health in adults.4 Developers have conducted investigations to determine the cutoff points of the ACQ that correspond to different levels of control. Established cutoffs include controlled asthma (ACQ score ≤0.75) and uncontrolled asthma (ACQ score ≥1.5).5 There is no clear evidence for the ACQ score cutoff to distinguish between not well controlled and very poorly controlled corresponding to the guideline-based levels above.6
Economic outcomes are an important part of optimizing asthma treatment given the reality of limited financial resources. According to the Global Initiative for Asthma, the main goal of asthma treatment is to achieve control and reduce risk of future exacerbations with regard to the cost of treatment.2 To understand the true effect of treatment, it is imperative to comprehensively understand the economic effect of changes in asthma control. A promising new asthma management program or intervention may result in improved control, but is it financially viable? Knowledge of the economic effect of improving asthma control is essential to answering this question.
Asthma results in increased health resource utilization (HRU) and expenditures.[7], [8] In particular, poorly controlled asthma has a significant negative effect on HRU and expenditures compared with adequately controlled asthma, and patients with the most severe disease account for most of the cost.[9], [10], [11], [12] Increasing scores (worsening asthma control) on the ACQ-5 (a 5-item patient-reported questionnaire about asthma symptoms) are strongly associated with increased HRU, expenditures, and risk of exacerbations in cross-sectional analyses of a general population of individuals with persistent asthma.13 However, little is understood about the association between clinical cutoff points of asthma control and economic outcomes. In addition, previous research on the economic effect of asthma control has been based on cross-sectional associations not longitudinal changes over time. Cross-sectional associations do not incorporate within-person improvement or deterioration over time. Given limited longitudinal estimates, most cost-effectiveness studies are forced to assume that cross-sectional associations are good proxies of actual longitudinal changes. Because all asthma interventions aim to improve control over time, longitudinal analyses are the most accurate means of estimating their effect. The purposes of this research are to explore the association of economic outcomes with cutoff points in asthma control via the ACQ-5 and to quantify the economic effect of changes in control level over time (ie, from very poorly controlled to controlled).
Section snippets
Data Source
The Observational Study of Asthma Control and Outcomes (OSACO) was a prospective survey and retrospective claims-based analysis of patients with persistent asthma 12 years or older who where patients of Kaiser Permanente of Colorado (KPCO).13 Eligible patients were sent surveys during 3 waves during 1 year between April 2011 and June 2012. The survey included questions on asthma control (ACQ-5), smoking status, sex, family income level, race, educational attainment, and ethnicity.
HRU and
Cross-sectional Analyses
Unadjusted HRU and expenditures by ACQ-5 scores cut by 0.5 are presented in Table 1. All measures of HRU and expenditures increased with increasing ACQ-5 scores. There were few individuals with ACQ-5 scores greater than 4.5, and estimates are much less consistent for these categories. Individuals with ACQ-5 scores between 4 and 4.5 filled 1.4 prescriptions for short-acting β-agonists (SABAs), had 3 outpatient visits (1.1 with asthma diagnosis), and incurred $7,298 (all-cause) and $4,108
Discussion
This research suggests that there is an economic benefit to improving asthma control over time in a general population. For example, improving patients progressing from very poorly controlled to controlled asthma resulted in a savings of $6,000 (4-month cost). In addition, this research reveals a strong association between greater HRU and expenditures and common cutoff points for poor control on the ACQ-5. It also provides preliminary information about which ACQ-5 points may be relevant cutoffs
Acknowledgment
We thank Denise Globe, PhD, for her valuable contribution to the conception and design of the study.
References (17)
- et al.
Asthma outcomes: composite scores of asthma control
J Allergy Clin Immunol
(2012) - et al.
Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire
Respir Med
(2006) - et al.
The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis
J Allergy Clin Immunol
(2013) - et al.
Patterns of asthma control: a 3-year analysis of patient claims
J Allergy Clin Immunol
(2005) - et al.
Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma
Ann Allergy Asthma Immunol
(2008) - et al.
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
Respir Med
(2005) - et al.
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation
J Allergy Clin Immunol
(2011) Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics–2002
J Allergy Clin Immunol
(2002)
Cited by (8)
Evaluating the effect of childhood and adolescence asthma on the household economy
2022, Jornal de PediatriaCitation Excerpt :In Portugal, 0.9% of the overall healthcare expenditures are directed to the care of children and adolescents’ asthma.8 Some countries spend more than 50% of the financial resources destined for asthma care on purchasing medicines,9,10 but spending money on asthma maintenance therapy is cost-effective. Countrywide studies showed that subsidizing inhaled medications for asthma, and other obstructive pulmonary diseases have contributed to reducing the rate of emergency room visits and hospital admissions, thus reducing the overall costs of these illnesses.1,11
Real-world evidence: Patient views on asthma in respiratory specialist clinics in America
2021, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :A more comprehensive knowledge of the patient’s level of control may lead to more appropriate treatment choices. As revealed in previous studies,2-6 we observed that asthma that was not well controlled was associated with increased use of rescue inhalers, systemic corticosteroids, markedly reduced HRQoL, increased number of exacerbations in the previous year, and increased HCRU compared with well-controlled asthma, reinforcing the importance of attaining and maintaining asthma control.18 Notably, the adverse impact on HRQoL found in the not well-controlled population in this study seemed to be comparable to the magnitude of HRQoL impairment found at baseline in other studies of biologic therapies,19 which generally recruited patients with more severe asthma than those included here.
Increasing our knowledge base of asthma
2017, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :As they noted, further work is needed to determine whether a decrease in chronic rhinosinusitis severity can reliably translate to improvement in asthma control. A study by Sullivan et al13 examined the association between asthma control cutoffs and longitudinal changes using the Asthma Control Questionnaire 5 (ACQ-5), with economic outcomes, and provided preliminary economic data on possible control cutoffs for the ACQ-5. Not surprising is that improved asthma control over time appeared to result in significant financial savings.
Short- and long-term oral steroid therapy in patients with asthma exacerbation
2023, Monaldi Archives for Chest DiseaseAssociation of low-dosage systemic corticosteroid use with disease burden in asthma
2020, npj Primary Care Respiratory Medicine
Disclosures: Dr Sullivan reported receiving research grants from Amgen Inc. Dr Globe reported being an employee of Amgen Inc. No other disclosures were reported.
Funding Sources: This study was funded by a research grant from Amgen Inc.